Skip to content
D-glutamate
D-glutamate is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart transplantationD016027EFO_001067311
Allergic conjunctivitisD003233EFO_0007141H10.4411
VertigoD014717H81.3911
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery bypassD001026EFO_000377622
LeukemiaD007938C9511
SarcomaD01250911
LymphomaD008223C85.911
Kidney neoplasmsD007680EFO_0003865C6411
Peripheral nervous system diseasesD010523G6411
Heart failureD006333EFO_0003144I5011
Postoperative complicationsD01118311
Myocardial infarctionD009203EFO_0000612I2111
Coronary artery diseaseD003324I25.111
Show 8 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C56112
Solitary pulmonary noduleD003074R91.122
Lung neoplasmsD008175C34.90122
Latent autoimmune diabetes in adultsD00007169811
Multiple pulmonary nodulesD05561311
Cervical intraepithelial neoplasiaD018290D0611
Non-small-cell lung carcinomaD002289111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C6111
Hiv infectionsD015658EFO_0000764B2011
ColitisD003092EFO_0003872K52.911
Colorectal neoplasmsD01517911
Fallopian tube neoplasmsD00518511
Hepatocellular carcinomaD006528C22.011
CholangiocarcinomaD018281C22.111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.911
Exploratory behaviorD005106EFO_000431611
EpilepsyD004827EFO_0000474G40.911
Persian gulf syndromeD018923EFO_000743011
Diet therapyD00403511
AtherosclerosisD050197EFO_0003914I25.111
Multiple sclerosisD009103EFO_0003885G3511
Autistic disorderD001321EFO_0003758F84.011
Gastroesophageal refluxD005764EFO_0003948K2111
Irritable bowel syndromeD043183EFO_0000555K5811
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameD-GLUTAMATE
INN
Description
D-glutamic acid is an optically active form of glutamic acid having D-configuration. It has a role as an Escherichia coli metabolite and a mouse metabolite. It is a D-alpha-amino acid and a glutamic acid. It is a conjugate acid of a D-glutamate(1-). It is an enantiomer of a L-glutamic acid.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N[C@H](CCC(=O)O)C(=O)O
Identifiers
PDB
CAS-ID6893-26-1
RxCUI
ChEMBL IDCHEMBL76232
ChEBI ID15966
PubChem CID23327
DrugBankDB02517
UNII ID
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details